SPON2 and prostate carcinoma: Supporting the notion of MINDIN upregulation in the serum of prostate cancer patients, some studies of other groups and ours have shown overexpression of MINDIN in prostate cancer compared to control tissue samples or cells [15,16,18,19,48,49].